GlassScriptPhysician profile
Karla R Shively
NPI 1871535450
$449.50
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $41.27 · 2021: $36.25.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $106.61 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $70.75 | 2019 | |
| Glaxosmithkline, LLC. | $55.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.61 | 2019 | |
| Amarin Pharma, INC. | $37.15 | 2019 | |
| Amgen INC. | $26.68 | 2019 | |
| Pfizer INC. | $21.47 | 2019 | |
| Tactile Systems Technology INC | $19.63 | 2019 | |
| Novo Nordisk INC | $17.30 | 2019 | |
| Sanofi Pasteur INC. | $15.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.11 | 2019 | |
| Horizon Therapeutics Plc | $12.50 | 2019 | |
| Hikma Pharmaceuticals USA | $10.84 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Shively listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.